Akums Drugs & Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd IPO

Akums Drugs & Pharmaceuticals Ltd IPO Price Range is ₹646 - 679, with a minimum investment of ₹14,938 for 22 shares.

₹14,938

/ 22 shares

Minimum Investment

View Akums Drugs & Pharmaceuticals Ltd IPO details including price range, minimum investment, lot size, financials, and IPO timeline. Get subscription updates, peer comparison, and key insights to help you make an informed decision.

IPO Status

Closed

Price Band

₹646 - 679

Open Date

2024-07-30

Close Date

2024-08-01

IPO Size

₹1,856.74 Cr

Lot Size

22 shares

Min Investment

₹14,938

Listing Exchange

NSE

Akums Drugs & Pharmaceuticals Ltd IPO Application Timeline

passed
Open Date30 Jul 2024
passed
Close Date1 Aug 2024
passed
Allotment Date2 Aug 2024
passed
Listing Date6 Aug 2024

IPO Subscription Status

IPO subscribed over

🚀 63.56x

This IPO has been subscribed by 21.3x in the retail category and 90.09x in the QIB category.

Subscription Rate

Total Subscription63.56x
Retail Individual Investors21.3x
Qualified Institutional Buyers90.09x
Non Institutional Investors42.21x
NameAkums Drugs & Pharmaceuticals Ltdx

Strengths and Risks

Strengths

Strengths

  • Largest India-focused CDMO serving the Indian domestic pharmaceutical industry.

  • Diverse client base with longstanding CDMO relationships.

  • Large and rapidly growing R&D capabilities across its product portfolio.

  • Strategic presence across the pharmaceutical value chain.

  • Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused PE investor.


Risks

Risks

  • Its manufacturing units and research and development centres are concentrated in Haridwar, Uttarakhand and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

  • Any slowdown or shutdown in its manufacturing and research and development operations could have an adverse effect on its business, results of operations, financial condition and cash flows.

  • Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.

  • Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on the companys business, results of operations, financial condition and cash flows.

  • The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.

  • The Company had issued Equity Shares to more than 49 investors in the past, which may have been in non-compliance with the Companies Act, 1956.

  • The company import some of its raw materials from China and other countries and source its remaining raw materials domestically. Any delay, interruption or reduction in the supply of such raw materials could adversely affect its business, financial condition and results of operations.

  • Its success depends on the companys ability to successfully develop and commercialize new products in a timely manner. Any failures to do so could adversely affect its business, results of operations and financial condition.

  • Certain of its corporate records, filings and instruments of transfer are not traceable. Its cannot assure you that no legal proceedings or regulatory actions will be initiated against the company in the future in relation to any such discrepancies.

  • The company has incurred losses in the past and may incur losses in the future.

How to Apply for Akums Drugs & Pharmaceuticals Ltd IPO on INDmoney

1

Download the INDmoney app and complete your KYC to open an account.

2

Go to the INDstocks section and tap on IPO, or search for ‘IPO’.

3

Select Akums Drugs & Pharmaceuticals Ltd IPO from the list of live IPOs.

4

View key details like price band, lot size, and dates, then tap ‘Apply Now’.

5

Choose the number of lots and place your order via UPI.

6

Your funds will be blocked until the share allotment is finalized.

About Akums Drugs & Pharmaceuticals Ltd

Bulkcorp International Limited is a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. The Company is also engaged in the sale of branded pharmaceutical formulations and manufacturing of active pharmaceutical ingredients. Some of its other services include formulation research and development, preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. Some of its manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.

IPO Objectives

  • Repayment or prepayment of indebtedness for Akums and its subsidiaries (Maxcure Nutravedics Ltd. and Pure and Cure Healthcare Pvt.)
  • Funding incremental working capital requirements
  • Pursuing inorganic growth initiatives through acquisitions
  • General corporate purposes
  • 86% of the IPO proceeds are allocated towards debt repayment (₹1599.1 Cr)


Services Offered:

  • Formulation research and development
  • Preparation and filing of regulatory dossiers in Indian and global markets
  • Other testing services


Production Capabilities:

  • Extensive range of dosage forms: tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies
  • Largest CDMO by production capacity in India for FY24, with 49.23 billion units annually, 4.5 times its second-largest peer


Expansion Plans:

  • Adding two new manufacturing units by FY 2025


Clientele:

  • Serves 26 of the top 30 pharmaceutical companies in India


Key Financial Highlights

BusinessFY 2024 (₹ in Crore)% of revenue from operations
CDMO3,266.3578.18%
Branded and generic formulations699.3216.74%
API212.525.09%
Total Revenue from Operations4,178.20100.00%
  • 78% of revenue from CDMO
  • Revenue grew nearly 14% to ₹4,212.21 crore in FY24 (from ₹3,700.93 crore in FY23)
  • Profit-after-tax declined 99.1% to ₹79 lakh in FY24 (from ₹97.82 crore in FY23)
  • Net worth fell 1% to ₹709.5 crore (from ₹717.19 crore in FY23)


Market Position

  • Largest domestic market-focused Indian CDMO on a revenue basis
  • 9.3% market share by value in the Indian domestic CDMO market (FY23)
  • 8.8% market share by volume in the total Indian Pharmaceutical Market (FY23)
  • 29.4% market share by value in the Indian domestic CDMO market (FY23)


Competitors

  • Tirupati Medicare
  • Innova Captab Ltd


Financial Results

YearRevenue (₹ in Crores)Revenue Change (%)PAT (₹ in Crores)PAT Change (%)
2022₹3694.52NA-₹250.87NA
2023₹3700.930.17%₹97.82138.99%
2024₹4212.2113.81%₹0.79-99.19%

Frequently Asked Questions of Akums Drugs & Pharmaceuticals Ltd IPO

What is the size of the Akums Drugs & Pharmaceuticals Ltd IPO?

The size of the Akums Drugs & Pharmaceuticals Ltd IPO is ₹1,856.74 Cr.

What is the allotment date of the Akums Drugs & Pharmaceuticals Ltd IPO?

Akums Drugs & Pharmaceuticals Ltd IPO allotment date is Aug 2, 2024 (tentative).

What are the open and close dates of the Akums Drugs & Pharmaceuticals Ltd IPO?

The Akums Drugs & Pharmaceuticals Ltd IPO will open on Jul 30, 2024 and close on Aug 1, 2024

What is the lot size of Akums Drugs & Pharmaceuticals Ltd IPO?

The lot size for the Akums Drugs & Pharmaceuticals Ltd IPO is 22.

When will my Akums Drugs & Pharmaceuticals Ltd IPO order be placed?

Your Akums Drugs & Pharmaceuticals Ltd IPO order will be placed on Jul 30, 2024

Can we invest in Akums Drugs & Pharmaceuticals Ltd IPO?

Yes, once Akums Drugs & Pharmaceuticals Ltd IPO opens, you can invest in the shares of the company.

What would be the listing gains on the Akums Drugs & Pharmaceuticals Ltd IPO?

The potential listing gains on the Akums Drugs & Pharmaceuticals Ltd IPO will depend on various market factors and cannot be predicted with certainty.

What is 'pre-apply' for Akums Drugs & Pharmaceuticals Ltd IPO?

'Pre-apply' for Akums Drugs & Pharmaceuticals Ltd IPO indicates your interest in the IPO before it opens for subscription. This ensures quick application when the IPO goes live.